If you've started Wegovy and it's working, a very natural question follows: how long do you actually stay on it? The answer isn't a fixed number of months. It depends on whether you're using the NHS or a private service, how your body responds, and what your long-term weight management goals look like.
What the evidence does make clear is this: Wegovy is designed for long-term use, not as a short course. Stopping it often leads to weight returning. That's not a reason to panic, but it is a reason to understand your options properly before making any decisions about duration or dose.
The short answer: privately prescribed Wegovy can be continued indefinitely if it remains effective and well-tolerated. NHS prescriptions are typically limited to 2 years under current NICE guidance. A lower maintenance dose is a legitimate option for some patients.
This guide covers what the clinical evidence says, how NHS and private routes differ, and what staying on a lower dose actually means in practice.
How long can you stay on Wegovy?
There's no universal time limit built into Wegovy itself. The treatment is licensed for chronic weight management, which means it's intended to be used over the long term, not stopped once you hit a target weight.
In clinical practice, how long you stay on it comes down to three things:
- Whether it's still working for you (meaningful weight loss or maintenance)
- Whether you're tolerating it without persistent side effects
- Which route you're on (NHS or private), since funding rules differ significantly
Wegovy through the NHS: the 2-year limit
If you've been prescribed Wegovy through the NHS, current NICE guidance recommends treatment for up to 2 years. NHS commissioning bodies build in review points at 6 months and beyond to assess whether you're meeting the expected benchmarks: typically at least 5% weight loss from your starting weight by month 3 on the maximum tolerated dose.
Some local NHS services set a firm 2-year maximum. Others allow continued use if you're still meeting clinical targets within a specialist weight management service. Scotland (via the Scottish Medicines Consortium) and Wales (via AWMSG) apply similar continuation principles, though exact timelines can vary by area.
The practical implication: if you're on the NHS pathway and approaching the 2-year mark, speak to your clinical team well in advance. Don't wait until your prescription ends to have that conversation.
Private Wegovy: no fixed end date
For patients accessing Wegovy through a private digital pharmacy such as Phlo Clinic, there's no mandatory time limit. Treatment can continue for as long as it remains clinically appropriate. That means your prescriber will review your progress regularly and continue prescribing if:
- You're maintaining or progressing towards a healthy weight
- Side effects are manageable or absent
- There are no new contraindications
This is the approach at Phlo Clinic. Our prescribing pharmacists carry out monthly check-ins to review your progress, adjust your dose if needed, and make sure treatment is still right for you. You're not left to manage this on your own.
Can you stay on Wegovy forever?
Technically, yes. Clinical trials provide reassuring safety data over several years of treatment. There's no clinical evidence that long-term Wegovy use causes harm in patients who tolerate it well. But "forever" isn't quite the right frame.
The better question is: does your body still need it?
Obesity is now widely recognised as a chronic condition, not a short-term problem you solve and move on from. The biology of weight regain is well-documented. When you stop semaglutide (Wegovy), the appetite-suppressing effects stop too. For many people, hunger returns to pre-treatment levels, and weight follows.
What the evidence says about stopping
The STEP 5 trial, published in Nature Medicine, followed 304 adults on semaglutide 2.4 mg for 104 weeks (2 years). Participants who continued treatment maintained an average weight loss of 15.2% of their starting body weight. Those who stopped regained a significant portion of that weight within a year.
The SELECT trial – a separate long-term study published in 2024, involving over 17,600 adults, found that weight loss with semaglutide continued for up to 65 weeks and was sustained for up to 4 years with ongoing treatment.
What this means in practice is Wegovy works while you're taking it. For most people, stopping means some weight returns. That's not a failure of willpower; it's a predictable biological response.
Who might consider stopping?
Stopping Wegovy may be appropriate if:
- You've reached a stable, healthy weight and feel confident you can maintain it through diet and lifestyle alone
- You experience persistent side effects that affect your quality of life and don't improve with a dose reduction
- You're planning a pregnancy (Wegovy is not recommended during pregnancy)
- Your prescriber advises it based on a clinical review
If you're thinking about stopping, always discuss it with your prescriber first. They can help you plan a gradual approach and put lifestyle support in place to protect your progress.
Can you stay on a low dose of Wegovy?
Yes, and this is a more common situation than many people realise. While 2.4 mg per week is the standard target maintenance dose, it isn't the right dose for everyone. Some patients find they achieve their goals at 1.7 mg, or that the higher dose causes side effects they'd rather avoid.
When a lower dose makes sense
Staying on a lower dose of Wegovy is clinically reasonable in a few situations:
What lower doses can and can't do
Wegovy's effects are dose-dependent. The most significant weight loss in clinical trials occurred at 2.4 mg. But that doesn't mean a lower dose is ineffective; it means the trade-off shifts from maximum weight loss to better tolerability.
1.7 mg is an established maintenance dose. If you can't tolerate 2.4 mg, your prescriber may keep you at 1.7 mg long term if it's still delivering results.
0.25 mg and 0.5 mg are initiation doses only. They're not intended for long-term use and haven't been studied in that context. If you're on one of these doses, the expectation is that you'll titrate upwards over time.
The key principle: lower doses still activate GLP-1 receptors and suppress appetite to some degree. For patients who've already lost significant weight, a lower dose may be enough to maintain that progress. But if your weight starts creeping back or hunger increases noticeably, it's a sign your current dose may need reviewing.
If you're considering staying on a lower dose, this is exactly the kind of decision that should be made with your prescribing pharmacist or clinician. At Phlo Clinic, our monthly check-ins are designed to catch these moments and adjust your plan accordingly.
What happens when you stop Wegovy?
Stopping Wegovy doesn't reverse your progress overnight, but the evidence is consistent: most people regain some weight after discontinuing treatment. Understanding why helps you plan for it, rather than be caught off guard.
The biology of weight regain
Semaglutide works by mimicking GLP-1, a hormone that regulates appetite and slows gastric emptying. When you stop taking it, those effects stop too. Hunger signals return to their pre-treatment levels. For many people, that means appetite increases, calorie intake rises, and weight follows.
This is why the STEP 5 trial data matters. Participants who stopped semaglutide after 2 years regained a significant proportion of the weight they'd lost within 12 months. It's not that the treatment "stopped working"; it's that the treatment was no longer present.
How do you maintain results after stopping Wegovy?
Some patients do maintain their results after stopping, particularly those who've used the treatment period to build sustainable eating habits and an active lifestyle. The medication can create a window of opportunity for lifestyle change. Whether that change sticks without the medication varies from person to person.
If you're planning to stop, the most protective approach is:
- Don't stop abruptly without a clinical conversation
- Have a maintenance plan in place: nutrition, activity, and regular weight monitoring
- Know the warning signs of regain early so you can act before significant weight returns
- Consider whether a lower dose might be a better middle ground than stopping entirely
Is long-term Wegovy use safe?
The safety profile of semaglutide at weight loss doses is well-established from clinical trials, and the evidence to date supports long-term use for appropriate patients.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These are most likely to occur when starting treatment or increasing the dose, and typically settle as your body adjusts. They're also more common at higher doses, which is one reason a lower maintenance dose can be worth considering for patients who are sensitive to them.
Serious side effects are less common but worth knowing about:
- Pancreatitis (inflammation of the pancreas): seek medical advice if you experience severe, persistent abdominal pain
- Gallbladder problems: gallstones are more common with rapid weight loss generally, not just with Wegovy
- Nutrient deficiencies: eating less over a long period can reduce your intake of key vitamins and minerals; a balanced diet and, where needed, supplementation helps manage this
There are also groups for whom Wegovy is not appropriate regardless of duration, including those who are pregnant, breastfeeding, or have a personal or family history of medullary thyroid carcinoma.
The overall picture: for patients who meet the prescribing criteria and are monitored regularly, the benefits of sustained treatment generally outweigh the risks. The key word is "monitored". Long-term Wegovy use should always be supervised by a qualified prescriber, not self-managed.
If you have questions about whether continued treatment is right for you, our common Wegovy side effects guide covers what to watch for in more detail.
Starting or continuing Wegovy with Phlo Clinic
Whether you're just starting out or you've been on Wegovy for a while and want to understand your long-term options, having a qualified prescriber in your corner makes a real difference.
At Phlo Clinic, our prescribing pharmacists review every patient individually. There's no one-size-fits-all approach to dose, duration, or what happens next. Monthly check-ins mean your treatment adapts as your needs change, whether that's adjusting your dose, discussing a maintenance plan, or helping you decide whether to continue or stop.
Explore Wegovy at Phlo Clinic to find out more about how our service works and what to expect from treatment.
FAQs
How long can you stay on Wegovy on the NHS?
Current NICE guidance supports treatment for up to 2 years. Some local commissioning bodies set a firm limit; others allow continuation if clinical benchmarks are met. Your clinical team will confirm what applies in your area.
Can you stay on Wegovy forever if you're using it privately?
Yes, if it remains effective and well-tolerated. There's no clinical upper limit for private prescriptions. Your prescriber will review your treatment regularly and continue it as long as it's appropriate for you.
Can you stay on a low dose of Wegovy long term?
Yes. 1.7 mg is a recognised maintenance dose and can be used long term if it's managing your weight effectively and you're tolerating it well. The standard initiation doses (0.25 mg and 0.5 mg) are not intended for long-term use. Any decision to stay on a lower dose should be made with your prescriber.
Will you regain weight if you stop?
Most people regain some weight after stopping. Clinical trial data shows that weight regain typically begins within weeks of discontinuation and can be significant within a year. Having a solid lifestyle and nutrition plan in place before stopping is important.
Is it safe to take Wegovy for years?
The available evidence supports long-term safety for appropriate patients under clinical supervision. Side effects are most common at the start of treatment or during dose increases, and typically improve over time. Regular monitoring is essential.
References
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28(10):2083-2091.
- Rubino DM, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425.
- National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity (TA875). Published 2023.
- Ryan DH, et al. Long-term weight loss results with semaglutide 2.4 mg: sustained outcomes over 4 years in 17,604 adults. Published 2024.
- European Medicines Agency. Wegovy: EPAR product information. Novo Nordisk A/S.
- Rubino D, et al. Rebound weight gain after stopping semaglutide: STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
